Global/integral assays in hemostasis diagnostics: Promises, successes, problems and prospects

Thrombosis Journal

Volumn 13, Issue 1, 2015, Pages

  Panteleev, Mikhail A ^a,b,c   Hemker, Hendrik Coenraad ^d  

^a CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

^b Federal Research and Clinical Center of Pediatric Hematology   (Russian Federation)

^c MOSCOW STATE UNIVERSITY   (Russian Federation)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT THERAPY; ASSAY; BLEEDING; BLOOD CLOTTING; BLOOD EXAMINATION; BLOOD GROUP; CLOT WAVEFORM ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; EDITORIAL; GLOBAL ASSAY; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; RISK; SENSITIVITY ANALYSIS; THROMBIN TIME; THROMBOELASTOGRAPHY; THROMBOSIS;

EID: 84938823121     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/s12959-014-0032-y     Document Type: Editorial

References (28)

1. Shah PK. Biomarkers of plaque instability. Curr Cardiol Rep. 2014;16:547.
2. Gandara E, Kovacs MJ, Kahn SR, Wells PS, Anderson DA, Chagnon I, et al. Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. Thromb Haemost. 2013;110:1172-9.
3. O'Donnell J, Boulton FE, Laffan MA. The relationship between plasma concentration of alpha2-macroglobulin and ABO blood group. Thromb Haemost. 2002;88:167-8.
4. Dentali F, Sironi AP, Ageno W, Bonfanti C, Crestani S, Frattini F, et al. Relationship between ABO blood group and hemorrhage: a systematic literature review and meta-analysis. Semin Thromb Hemost. 2013;39:72-82.
5. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol. 1994;88:601-7.
6. Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122:1873-80.
7. Lipets E, Vlasova O, Urnova E, Margolin O, Soloveva A, Ostapushchenko O, et al. Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients. PLoS One. 2014;9:e87692.
8. Minnema MC, Peters RJ, de Winter R, Lubbers YP, Barzegar S, Bauer KA, et al. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20:2489-93.
9. Kohler HP, Carter AM, Stickland MH, Grant PJ. Levels of activated FXII in survivors of myocardial infarction-association with circulating risk factors and extent of coronary artery disease. Thromb Haemost. 1998;79:14-8.
10. Panteleev MA, Vasil'ev SA, Sinauridze EI, Vorobyev AI, Ataullakhanov FI. Practical Coagulation Science [in Russian]. Moscow; 2010.
11. Al Dieri R, Alban S, Beguin S, Hemker HC. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost. 2006;4:83-9.
12. Danforth CM, Orfeo T, Everse SJ, Mann KG, Brummel-Ziedins KE. Defining the boundaries of normal thrombin generation: investigations into hemostasis. PLoS One. 2012;7:e30385.
13. Tarandovskiy ID, Balandina AN, Kopylov KG, Konyashina NI, Kumskova MA, Panteleev MA, et al. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Thromb Res. 2013;131:e274-80.
14. Brummel-Ziedins KE, Wolberg AS. Global assays of hemostasis. Curr Opin Hematol. 2014;21:395-403.
15. van Geffen M, van Heerde WL. Global haemostasis assays, from bench to bedside. Thromb Res. 2012;129:681-7.
16. Hemker HC, Al Dieri R, Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol. 2004;11:170-5.
17. Eilertsen AL, Liestol S, Mowinckel MC, Hemker HC, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thromb Haemost. 2007;97:938-43.
18. Yamaguchi Y, Moriki T, Igari A, Matsubara Y, Ohnishi T, Hosokawa K, et al. Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals. Thromb Res. 2013;132:263-70.
19. Brinkman HJM. Global assays and the management of oral anticoagulation. Thromb J. 2014, This collection: in press.
20. Lance M. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Thromb J. 2014, This collection: in press.
21. Lipets EN, Ataullakhanov FI. Global assays of hemostasis in the diagnostics of coagulation and evaluation of thrombosis risks. Thromb J. 2014, This collection: in press.
22. Tynngard N, Lindahl TL, Ramstrom S. Assays of different aspects of hemostasis - what do they measure? Thromb J. 2014, This collection: in press.
23. Dashkevich NM, Vuimo TA, Ovsepyan RA, Surov SS, Soshitova NP, Panteleev MA, et al. Effect of pre-analytical conditions on the thrombodynamics assay. Thromb Res. 2014;133:472-6.
24. Curvers J, Christella M, Thomassen LG, de Ronde H, Bertina RM, Rosendaal FR, et al. Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assay. Thromb Haemost. 2002;87:483-92.
25. Dargaud Y, Wolberg AS, Luddington R, Regnault V, Spronk H, Baglin T, et al. Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study. Thromb Res. 2012;130:929-34.
26. Brummel-Ziedins KE, Orfeo T, Rosendaal FR, Undas A, Rivard GE, Butenas S, et al. Empirical and theoretical phenotypic discrimination. J Thromb Haemost. 2009;7 Suppl 1:181-6.
27. Hemker HC, Kerdelo S, Kremers RM. Is there value in kinetic modeling of thrombin generation? No (unless...). J Thromb Haemost. 2012;10:1470-7.
28. Willems GM, Lindhout T, Hermens WT, Hemker HC. Simulation model for thrombin generation in plasma. Haemostasis. 1991;21:197-207.